Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

I. Bahce; M. Yaqub; E. F. Smit; A. A. Lammertsma; G. A.M.S. van Dongen; N. H. Hendrikse

doi:https://doi.org/10.1016/j.lungcan.2016.05.025

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

I. Bahce, M. Yaqub, E. F. Smit, A. A. Lammertsma, G. A.M.S. van Dongen, N. H. Hendrikse

Research output: Contribution to journal › Article › Academic › peer-review

29 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

Original language	English
Pages (from-to)	1-13
Number of pages	13
Journal	Lung Cancer
Volume	107
DOIs	https://doi.org/10.1016/j.lungcan.2016.05.025
Publication status	Published - 1 May 2017

Keywords

NSCLC
PET
TKI-PET
immuno-PET

Access to Document

https://doi.org/10.1016/j.lungcan.2016.05.025

Cite this

@article{1b94782b753c4d82b66efcb1eaa2232e,

title = "Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET",

abstract = "Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.",

keywords = "NSCLC, PET, TKI-PET, immuno-PET",

author = "I. Bahce and M. Yaqub and Smit, {E. F.} and Lammertsma, {A. A.} and {van Dongen}, {G. A.M.S.} and Hendrikse, {N. H.}",

year = "2017",

month = may,

day = "1",

doi = "https://doi.org/10.1016/j.lungcan.2016.05.025",

language = "English",

volume = "107",

pages = "1--13",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

AU - Bahce, I.

AU - Yaqub, M.

AU - Smit, E. F.

AU - Lammertsma, A. A.

AU - van Dongen, G. A.M.S.

AU - Hendrikse, N. H.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

AB - Non-small cell lung cancer (NSCLC) therapy has entered a rapidly advancing era of precision medicine with an ever increasing number of drugs directed against a variety of specific tumor targets. Amongst these new agents, tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) are most frequently used. However, as only a sensitive subgroup of patients benefits from targeting drugs, predictive biomarkers are needed. Positron emission tomography (PET) may offer such a biomarker for predicting therapy efficacy. Some of the TKIs and mAbs that are in clinical use can be radioactively labeled and used as tracers. PET can visualize and quantify tumor specific uptake of radiolabeled targeting drugs, allowing for characterization of their pharmacokinetic behavior. In this review, the clinical potential of PET using radiolabeled TKIs (TKI-PET) and mAbs (immuno-PET) in NSCLC is discussed, and an overview is provided of the most relevant preclinical and clinical studies.

KW - NSCLC

KW - PET

KW - TKI-PET

KW - immuno-PET

UR - http://www.scopus.com/inward/record.url?scp=85008194201&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.lungcan.2016.05.025

DO - https://doi.org/10.1016/j.lungcan.2016.05.025

M3 - Article

C2 - 27319335

SN - 0169-5002

VL - 107

SP - 1

EP - 13

JO - Lung Cancer

JF - Lung Cancer

ER -

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

Abstract

Keywords

Access to Document

Other files and links

Cite this